ERCICEK, Fatma; HARSCOAT-SCHIAVO, Christelle; MARCHIVIE, Mathieu; MARRE, Samuel; SUBRA-PATERNAULT, Pascale

Chimie et Biologie des Membranes et des Nanoobjets [CBMN]

HARSCOAT-SCHIAVO, Christelle
Chimie et Biologie des Membranes et des Nanoobjets [CBMN]

MARCHIVIE, Mathieu

Langue

Communication dans un congrès

Ce document a été publié dans

27th International Workshop on Industrial Crystallization, 2022-08-31, Espoo. 2022-08-31

Résumé en anglais

Co-crystalline products are becoming increasingly important in the pharmaceutical industry, due to the chirality, low water solubility and low bioavailability of most active pharmaceutical ingredients (API). Solids with a single crystalline phase composed of two entities (API + coformer COF) linked via non-covalent interactions are called co-crystals. The modification of the API crystal lattice through the incorporation of the COF enhances the physicochemical properties of the initial drug without altering its therapeutic purposes. Thus, understanding crystallization processes can help to obtain products with desired properties. The formation of metastable conglomerates by co-crystallization can be a solution for optical resolution< Réduire

Mots clés en anglais

Co-crystallization

Supercritical CO2

Chiral resolution

In-situ observations

Microfluidics

URI

https://oskar-bordeaux.fr/handle/20.500.12278/199208

Project ANR

Apport du CO2 dans le contrôle de phase cristalline - ANR-18-CE07-0047

Unités de recherche

CBMN : Chimie & de Biologie des Membranes & des Nano-objets - UMR 5248

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Investigations of pharmaceutical compounds co-crystallization for application to chiral resolution assisted by supercritical CO2